Mohammed Mahmoud, MD, MS provides an insightful overview of key findings presented at the 2024 American Urological Association conference concerning metastatic prostate cancer. Key highlights included discussions on prostate-specific membrane antigen (PSMA) targeting for diagnostics and therapeutics, genetic testing, and multidisciplinary treatment approaches. Of note, the PSMAfore study showcased the efficacy of lutetium-based PSMA therapy in chemotherapy-naive patients with metastatic prostate cancer, demonstrating superior outcomes in terms of radiographic progression-free survival and PSA decline.
In addition, promising results from a phase 1/2 study of PSMA-targeted actinium-J591 were presented, showing feasibility and potential efficacy in heavily treated patients. The TARGET study emphasized the importance of genetic testing, revealing significant rates of pathologic mutations and underscoring the need for incorporating Fanconi anemia genes in panels for younger patients with prostate cancer.
Medscape © 2024 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: AUA 2024: New Data on PSMA Targeting and Genetic Testing - Medscape - May 10, 2024.
Comments